Aprogen Biologics Inc. (KRX:003060)
South Korea flag South Korea · Delayed Price · Currency is KRW
251.00
+12.00 (5.02%)
Apr 14, 2026, 7:45 AM KST

Aprogen Biologics Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Operating Revenue
73,22667,37887,36465,19056,482
Upgrade
Other Revenue
0----
Upgrade
Revenue
73,22667,37887,36465,19056,482
Upgrade
Revenue Growth (YoY)
8.68%-22.88%34.01%15.42%5.93%
Upgrade
Cost of Revenue
100,58075,22499,33739,38031,607
Upgrade
Gross Profit
-27,354-7,846-11,97425,81024,875
Upgrade
Selling, General & Admin
28,05626,34329,78928,91425,947
Upgrade
Research & Development
4,00318,03515,0002,1871,735
Upgrade
Amortization of Goodwill & Intangibles
0.7613.9319.4645.8133.95
Upgrade
Other Operating Expenses
576.4383.38357.6365.27416.95
Upgrade
Operating Expenses
95,53650,73058,71630,01528,850
Upgrade
Operating Income
-122,889-58,577-70,690-4,204-3,975
Upgrade
Interest Expense
-10,700-5,514-3,668-274.41-31.14
Upgrade
Interest & Investment Income
9,8754,2424,48816,64513,587
Upgrade
Earnings From Equity Investments
-285.519,01879,78694.73352.2
Upgrade
Currency Exchange Gain (Loss)
242.83-20.53-6.2233.1612.72
Upgrade
Other Non Operating Income (Expenses)
42,741-10,015564.26209.78347.85
Upgrade
EBT Excluding Unusual Items
-81,016-50,86510,47412,50410,294
Upgrade
Gain (Loss) on Sale of Investments
-86,707-57,99929,9502,6381,623
Upgrade
Gain (Loss) on Sale of Assets
88.6916.15-151,5373.153.08
Upgrade
Asset Writedown
-637.76-154.08-2,271-264.15-2,134
Upgrade
Other Unusual Items
-1,1064,023--1.04-4.76
Upgrade
Pretax Income
-169,378-104,980-113,38314,8819,831
Upgrade
Income Tax Expense
-1,081-1,9471,260679.69
Upgrade
Earnings From Continuing Operations
-168,297-104,980-115,33013,6219,151
Upgrade
Minority Interest in Earnings
-2,0340.72-2,940-981.32-1,048
Upgrade
Net Income
-170,331-104,979-118,27012,6398,103
Upgrade
Net Income to Common
-170,331-104,979-118,27012,6398,103
Upgrade
Net Income Growth
---55.99%-27.99%
Upgrade
Shares Outstanding (Basic)
138433
Upgrade
Shares Outstanding (Diluted)
138433
Upgrade
Shares Change (YoY)
57.17%99.30%56.07%1.42%25.52%
Upgrade
EPS (Basic)
-12930.00-12525.00-28122.144690.383049.36
Upgrade
EPS (Diluted)
-12930.00-12525.00-28125.004650.003000.00
Upgrade
EPS Growth
---55.00%-42.86%
Upgrade
Free Cash Flow
-47,857-46,261-61,73924,444-7,023
Upgrade
Free Cash Flow Per Share
-3632.91-5519.38-14680.219071.14-2642.97
Upgrade
Gross Margin
-37.35%-11.64%-13.71%39.59%44.04%
Upgrade
Operating Margin
-167.82%-86.94%-80.92%-6.45%-7.04%
Upgrade
Profit Margin
-232.61%-155.81%-135.38%19.39%14.34%
Upgrade
Free Cash Flow Margin
-65.36%-68.66%-70.67%37.50%-12.43%
Upgrade
EBITDA
-103,705-39,486-49,292-1,800-1,903
Upgrade
EBITDA Margin
-141.62%-58.60%-56.42%-2.76%-3.37%
Upgrade
D&A For EBITDA
19,18519,09021,3982,4042,072
Upgrade
EBIT
-122,889-58,577-70,690-4,204-3,975
Upgrade
EBIT Margin
-167.82%-86.94%-80.92%-6.45%-7.04%
Upgrade
Effective Tax Rate
---8.47%6.91%
Upgrade
Advertising Expenses
445.33521.48736.691,3717,800
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.